KRAS and pancreatic adenocarcinoma: A further important open issue is targeting non-G12C KRAS mutations; for instance, KRAS G12V mutation, although more common in colorectal cancers (CRC) or pancreatic adenocarcinomas, accounts for about 6% of NSCLC mutations.